Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | Tom Wetherald and Eddie ReillyMinot Light Capital Partners | Journey Medical $DERM• NASDAQ | PharmaceuticalsPharmaceuticals | Long DERM (Journey Medical) Journey Medical represents a compelling specialty pharmaceutical play backed by its recent FDA approval of Emrosi for treating Rosacea. Emrosi has shown... | BULL | View Pitch → |
| Aug 20, 2026 | Seeking Alpha | Seeking Alpha ContributorSeeking Alpha | Journey Medical $DERM• NASDAQ | PharmaceuticalsPharmaceuticals | Journey Medical Corporation Journey Medical Corporation, despite a challenging year-to-date performance, shows promising signs of recovery and growth. The company's Q2... | BULL | View Pitch → |
| Jan 8, 2026 | Fund Letter | Andrew SummersSummers Value Fund | Journey Medical $DERM• NASDAQ | PharmaceuticalsPharmaceuticals | Summers Value Fund 2025 Q2 (DERM) We began building a position in Journey Medical in February. Journey is a... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.